// App-Quantinova.ai

2728 : Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

Researchers

Presenter

  • In-Ho Song

Principal Investigators

  • Aileen Pangan

  • Atul Deodhar

  • Filip Van den Bosch

  • Walter P. Maksymowych

  • Tae-Hwan Kim

  • Mitsumasa Kishimoto

  • Andrea Everding

  • Yunxia Sui

  • Xin Wang

  • Alvina D. Chu

  • Joachim Sieper

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • AbbVie Inc., North Chicago, IL, USA, North Chicago, IL

  • AbbVie, Inc., North Chicago, IL

  • Oregon Health and Science University, Portland, OR

  • Ghent University Hospital, Ghent, Belgium

  • University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

  • Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

  • Imuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

  • HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany

  • AbbVie, Inc., North Chicago, IL

  • Charite Universitaetsmedizin Berlin, Medical Oncology, Berlin, Germany

Locations

  • Netherlands

  • United States

  • Belgium

  • Canada

  • Japan

  • Germany

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved